基本信息
浏览量:172
职业迁徙
个人简介
His principal interest in medical oncology is breast cancer, especially in the adjuvant/neoadjuvant settings. He is deeply involved in the conduct of large phase III trials in breast cancer (some of them practice changing), such as HERA (adjuvant trastuzumab), ALTTO (trastuzumab and/or lapatinib), APHINITY (trastuzumab with or without pertuzumab), Alexandra (adjuvant atezolizumab in triple negative breast cancer), Olympia (adjuvant Olaparib) and – in the neoadjuvant setting – the LORELEI trial which tested the efficacy of PI3K inhibition in combination with endocrine therapy (Global PI). He is also engaged in studies concerning cancer toxicity of new drugs in oncology as well as in long-term follow-up of patients enrolled in clinical trials, with a focus on cardiotoxicity. Within the latter context, he was a co-author of guidelines on treatment-related cardiac toxicity by the European Society for Medical Oncology (ESMO) and the European Society of Cardiology (ESC) and has been acting as a member of the ESC Council for cardio-oncology for the past few years. He is also a past chair of the survivorship task force of the Belgian Society of Medical Oncology (BSMO).
研究兴趣
论文共 451 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
EUROPEAN JOURNAL OF CANCER (2024): 113478-113478
ONCOLOGY AND THERAPYno. 1 (2024): 19-29
ONCOLOGY AND THERAPYno. 1 (2024): 19-29
crossref(2024)
The Lancet Oncologyno. 2 (2024): e73-e83
Breast Cancer Research and Treatmentno. 2 (2024): 351-363
Clinical Breast Cancer (2024)
crossref(2024)
Mariana Brandão,Diogo Martins-Branco,Claudia De Angelis,Peter Vuylsteke, Richard D. Gelber,Nancy Van Damme, Lien van Walle,Arlindo R. Ferreira, Matteo Lambertini,Francesca Poggio, Didier Verhoeven,Annelore Barbeaux,
CANCER RESEARCHno. 5 (2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn